BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 36353552)

  • 1. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
    Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
    Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
    J Thorac Cardiovasc Surg; 2024 Feb; ():. PubMed ID: 38342430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis.
    Zhao J; Hao S; Li Y; Liu X; Liu Z; Zheng C; Han D
    Immunotargets Ther; 2023; 12():113-133. PubMed ID: 38026088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    Zhang C; Hong HZ; Wu YL; Zhong WZ
    JTCVS Open; 2021 Dec; 8():588-607. PubMed ID: 36004199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
    Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
    Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
    Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
    Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
    Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
    Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
    Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
    EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
    Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
    Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study.
    Duan H; Wang T; Luo Z; Tong L; Dong X; Zhang Y; Afzal MZ; Correale P; Liu H; Jiang T; Yan X
    Transl Lung Cancer Res; 2021 Feb; 10(2):1020-1028. PubMed ID: 33718040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer.
    Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z
    Front Immunol; 2023; 14():1268251. PubMed ID: 37818382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection 
after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer].
    Liu X; Sun T; Hong T; Yuan Y; Zhang H
    Zhongguo Fei Ai Za Zhi; 2022 Feb; 25(2):71-77. PubMed ID: 35224959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC).
    Wang Q; Qi C; Luo J; Xu N; Xu MT; Qiang Y; Zhang C; Shen Y
    Front Oncol; 2023; 13():1239451. PubMed ID: 38205138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
    Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
    J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
    Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
    Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer.
    Zheng J; Li Y; Jin C; Ruan K; Sun K; Chen H; Wang M; Zhang S; Zhou J; Zhou J
    Lung Cancer; 2023 Oct; 184():107326. PubMed ID: 37579576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.
    Qi Y; Gu L; Shen J; Yao Y; Zhao Y; Lu S; Chen Z
    Front Oncol; 2023; 13():1194100. PubMed ID: 37655106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
    Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
    J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.